Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ).
Qyuns Therapeutics Co., Ltd. has received approval from the Hong Kong Stock Exchange for the full circulation of its H shares, marking a significant milestone in its listing process. This approval allows three participating shareholders to convert 17,322,400 domestic shares into H shares, which will constitute approximately 7.80% of the company’s total issued H shares, potentially enhancing liquidity and market presence.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a joint stock company incorporated in China, operating in the biotechnology industry. The company focuses on the development and commercialization of therapeutic products, with a market focus on innovative medical solutions.
YTD Price Performance: 65.31%
Average Trading Volume: 55,872
Technical Sentiment Consensus Rating: Strong Buy
Learn more about 2509 stock on TipRanks’ Stock Analysis page.